Business
NXP002 Inflammation and Duration of Action Update
NXP002 Inflammation and Duration of Action Update.
About this update from Nuformix Plc
[{"type":"text","content":"\n\n18 May 2023\n \nNuformix plc\n \n(\"Nuformix\" or the \"Company\" or the \"Group\")\n \nNXP002 - Inflammation and Duration of Action Update\n \nNuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the following update regarding the Company's NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis (\"IPF\").\n \nThe Company recently announced that it was undertaking studies measuring NXP002's modulation of inflammation-related biomarkers alone and in combination with current IPF standards of care (\"SoC\") in a novel 3D human IPF lung tissue model, in addition to the use of an exploratory healthy human lung tissue model to investigate NXP002's duration of action. The study results are described below.\n \nInflammation\n \nFollowing success in supressing biomarkers of fibrotic disease progression in human IPF lung tissue, the same samples were analysed to assess additional mechanistic and anti-inflammatory benefits on top of SoC's and the results are summarised as follows:\n \n· NXP002 alone delivers a strong, consistent anti-inflammatory effect as demonstrated by suppression of the release of inflammatory cytokines by over 90% for all cytokines studied;\n· Both high and low concentrations of NXP002 show an additional anti-inflammatory effect in the presence of SoC's and enhance their anti-inflammatory performance;\n· This effect is most pronounced for MCP-1, which is most closely linked with the progression of IPF\n· The results further suggests that NXP002 will provide additional efficacy in combination with SoC's, even in patients responding to SoC therapy alone. The data also continues to support the possibility that NXP002 targets additional disease pathways to SoC's, increasing the combined anti-fibrotic and anti-inflammatory responses.\n \nOverall, the results strengthen NXP002's potential to increase efficacy of existing therapies with the benefits of inhaled delivery (e.g. added efficacy without increased side effects). They also support NXP002's potential as a monotherapy for patients non-responsive to SoCs and those declining these therapies due to side ef...